Sign in
Taking peopleNo phase

HighFLO Study - HighLife Trans-septal Mitral Valve Replacement (TSMVR) Feasibility Study of the Open Cell CLARITY Valve

Key facts

Who runs it
HighLife SAS
Where
Australia, Belgium, France, Germany, Poland, and United Kingdom14 sites in 6 countriesChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
30 people, planned
Started
1 Jul 2021
Expected to end
1 Feb 2031
Type of study
Interventional
Treatments tested
  • CLARITY
Record updated
3 October 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • Age ≥ 18 years
  • Moderate-severe or severe mitral regurgitation (≥ 3+)
  • Patient has New York Heart Association (NYHA) Functional Class II, III or ambulatory IV
  • Patient is under guideline directed medical therapy for at least one month, as reviewed and confirmed by the local multidisciplinary Heart Team
  • Patient is high-risk for open-heart surgery based on the assessment of the multidisciplinary Heart Team using standard scoring systems and consideration of co-morbidities, frailty, and disability
  • Patient meets the anatomical criteria for HighLife valve
  • Patient is willing to participate in the study and provides signed informed consent
  • Patients with a high risk for LVOTO

Who cannot take part

  • Patient cannot tolerate anticoagulation or antiplatelet therapy
  • Any stroke/TIA within 30 days
  • Active infections requiring antibiotic therapy
  • Active ulcer or gastro-intestinal bleeding in the past 3 months
  • History of bleeding diathesis, coagulopathy or refusal of future blood transfusion
  • Patient has known allergies to the device components or contrast medium
  • Patients with a life expectancy of less than 12 months due to non-cardiac conditions
  • Patient had permanent pacemaker, or similar device with implantable cardiac leads (i.e. resynchronization therapy) within the last 3 months; -
  • Severe symptomatic carotid stenosis (> 70% by non-invasive imaging)
  • Patients in whom TEE is not feasible
  • Patients who are pregnant or lactating, or plan to get pregnant in the next 12 months
  • Patient is unable to comply with the follow-up schedule and assessments
  • Participation in another clinical investigation at the time of inclusion

This trial has no sites in United States.

It has sites in 6 countries. Choose a country to see its sites.

About the trial

What the trial wants to find out

Feasibility, safety and performance of the HighLife CLARITY TSMV and its delivery system

The group in the trial

  • TreatmentTreatment being tested

    Trans-septal mitral valve replacement

    Treatment: CLARITY

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
HighLife TSMVR Feasibility Study of the Open Cell CLARITY Valve in Patients With Moderate-severe or Severe MR, High Surgical Risk and With a High Risk for Left Ventricular Outflow Tract Obstruction (LVOTO)
Record updated
3 October 2024